ip-001
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2019 (NCT03993678)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06526338 | Phase 2 | Jul 24, 2024 | University of Louisville |
| NCT06630624 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2024 | Angiodynamics, Inc., Free University of Amsterdam, Immunophotonics, Inc. |
| NCT05688280 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2022 | Cantonal Hospital of St. Gallen, Immunophotonics, Inc. |
| NCT03993678 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2019 | Cantonal Hospital of St. Gallen, Swiss Group for Clinical Cancer Research |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cantonal Hospital of St. Gallen | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Immunophotonics, Inc. | For profit | 2 | 1 | 1 | 2022 |
| Angiodynamics, Inc. | For profit | 1 | 0 | 1 | 2024 |
| Free University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Swiss Group for Clinical Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Louisville | Academic/Hospital | 1 | 1 | 1 | 2024 |
6 organizations
Page 1 / 1